Table 3.
Pre- and post-operative therapies and outcome.
| Case | Preoperative treatment | Postoperative treatment | Outcome |
|---|---|---|---|
| 1 | IA HA/TA in DIPJ/NB | IA HA/TA in DIPJ | Fail |
| 2 | IA HA/TA in DIPJ/NB | IA PRP/ACS | Fail |
| 3 | IA HA/TA in DIPJ/NB | IA BM-MSC | Success |
| 4 | Unknown | IA BM-MSC | Fail |
| 5 | IA HA/TA in DIPJ/NB | IA BM-MSC | Fail |
| 6 | IA HA/TA in DIPJ | IA PRP/Stanozolol | Fail |
| 7 | Multiple (eight) IA HA/TA in DIPJ/NB (one); IA Stanozolol DIPJ (three) | IA ACS | Fail |
| 8 | IA HA/TA in DIPJ/NB; IA Stanozolol in DIPJ | IA PRP/ACS | Success |
| 9 | IA HA/TA in DIPJ (two) | IA HA/PSGAG | Success |
| 10 | IA HA/TA in DIPJ | IA PSGAG | Success |
TA — triamcinolone acetonide; NB — navicular bursa; PRP — platelet-rich plasma; ACS — autologous conditioned serum; BM-MSC — bone marrow derived mesenchymal stem cells; PSGAG — polysulfonated glycosaminoglycan; HA — hyaluronic acid; DIPJ — distal interphalangeal joint.